Luke Nicholls - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Luke Nicholls's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Luke Nicholls
Verified
Publisher, edie
West Village
Beats
Military aviation in North and South America
Non
Content
Simultaneous focal boost with stereotactic radiotherapy for localised intermediate to high-risk prostate cancer: Primary outcomes of the SPARC phase II trial
By W Smithfield, Luke Nicholls Verified, Raymond Terrace, Daniel Henderson| International Journal of Radiation Oncology*Biology*Physics Verified Abstract : Dose escalated radiotherapy is associated with better biochemical control at the expense of toxicity. Stereotactic body radiotherapy (SBRT) with dose escalation to the dominant intraprostatic lesion (DIL) provides a logical approach to improve outcomes in high-risk disease whilst limiting toxicity. This study evaluated the toxicity and quality of life (QOL) with CyberKnife-based SBRT and simultaneous integrated boost in localised prostate cancer.
By Luke Nicholls Verified| edie Verified edie's long-running SustyTalk series evolved at the Sustainability Leaders Forum in March, with the edie team delivering in-person discussions with notable sustainability professionals. Up next, Enapter co-founder Vaitea Cowan and Costain's climate change director Lara Young. Taking place at the Sustainability Leaders Forum earlier this month (8-9) March, the SustyTalk Live series is an evolution of edie’s traditional SustyTalk interviews.
Simultaneous focal boost with stereotactic radiotherapy for localised intermediate to high-risk prostate cancer: Primary outcomes of the SPARC phase II trial
By W Smithfield, Luke Nicholls Verified, Raymond Terrace, Daniel Henderson| International Journal of Radiation Oncology*Biology*Physics Verified Abstract : Dose escalated radiotherapy is associated with better biochemical control at the expense of toxicity. Stereotactic body radiotherapy (SBRT) with dose escalation to the dominant intraprostatic lesion (DIL) provides a logical approach to improve outcomes in high-risk disease whilst limiting toxicity. This study evaluated the toxicity and quality of life (QOL) with CyberKnife-based SBRT and simultaneous integrated boost in localised prostate cancer.
Company Info
edie
Edie is a leadership and HR development professional, specializing in online and workshop development and facilitation. Drawing on more than 20 years of experience in public and private sector organizations, she combines theory with practical business applications to help people understand and apply new skills and approaches in their professional and personal lives. Edie holds a B.Admin from the University of Athabasca and a Certificate in Continuing Adult Education (CACE) from the University of Alberta.
England, West, United Kingdom
+1 224-985-3135